Document Detail


B-cell-depleting therapy in systemic lupus erythematosus.
MedLine Citation:
PMID:  22444096     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The emergence of a new class of agents (B-cell-depleting therapies) has opened a new era in the therapeutic approach to systemic lupus erythematosus, with belimumab being the first drug licensed for use in systemic lupus erythematosus in more than 50 years. Four agents deserve specific mention: rituximab, ocrelizumab, epratuzumab, and belimumab. Controlled trials have shown negative results for rituximab, promising results for epratuzumab, and positive results for belimumab. Despite these negative results, rituximab is the most-used agent in patients who do not respond or are intolerant to standard therapy and those with life-threatening presentations. B-cell-depleting agents should not be used in patients with mild disease and should be tailored according to individual patient characteristics, including ethnicity, organ involvement, and the immunological profile. Forthcoming studies of B-cell-directed strategies, particularly data from investigations of off-label rituximab use and postmarketing studies of belimumab, will provide new insights into the utility of these treatments in the routine management of patients with systemic lupus erythematosus.
Authors:
Manuel Ramos-Casals; Iñaki Sanz; Xavier Bosch; John H Stone; Munther A Khamashta
Related Documents :
1718706 - Serial eeg in alzheimer's disease: 3 year follow-up and clinical outcome.
14676056 - Comparison of the short test of mental status and the mini-mental state examination in ...
22434306 - Antiphospholipid antibody-related bell's palsy in young women.
15021866 - Valproate use in neuropsychiatric disorders in the elderly.
16641656 - Racial differences in impact of coverage on diabetes self-monitoring in a health mainte...
16594246 - The prevalence of psychiatric disorder and the wish to hasten death among terminally il...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  125     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-26     Completed Date:  2012-05-14     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  327-36     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
B-Lymphocytes / immunology*
Humans
Lupus Erythematosus, Systemic / drug therapy*,  immunology
Randomized Controlled Trials as Topic
Grant Support
ID/Acronym/Agency:
P01 AI078907/AI/NIAID NIH HHS; R37 AI049660/AI/NIAID NIH HHS; U19 AI056390/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Monoclonal, Murine-Derived; 0/epratuzumab; 0/ocrelizumab; 0/rituximab; 73B0K5S26A/belimumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of fish oil on ruminal biohydrogenation of C18 unsaturated fatty acids in steers fed grass or...
Next Document:  Digitalis toxicity: a fading but crucial complication to recognize.